On January 16, 2025, the Food and Drug Administration approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for adult patients with KRAS G12C-mutated metastatic...

Oct 22, 2023 · KRAS G12C is a mutation that occurs in approximately 3 to 4% of patients with metastatic colorectal cancer. Monotherapy with KRAS G12C inhibitors has yielded only modest efficacy....

Jun 21, 2024 · The US Food and Drug Administration has granted accelerated approval for the targeted therapy adagrasib (Krazati ®) in combination with the drug cetuximab (Erbitux ®) for people with advanced colorectal cancer caused by a gene mutation called KRAS-G12C.

Jan 17, 2025 · "This new option validates our combination approach to improve outcomes for patients living with advanced KRAS G12C-mutated metastatic colorectal cancer." Colorectal cancer is the third leading cause of cancer-related deaths in the United States, and fewer than one in five people diagnosed with metastatic disease survive beyond five years after ...

Dec 21, 2022 · Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has shown clinical activity in pretreated patients with several tumor types, including colorectal cancer. Preclinical...

Apr 15, 2024 · KRAS mutations contribute substantially to the overall colorectal cancer burden and have long been a focus of drug development efforts. After a lengthy preclinical road, KRAS inhibition via the G12C allele has finally become a therapeutic reality.

Jan 16, 2025 · The following is a message from the Director of the FDA Oncology Center of Excellence, Dr. Richard Pazdur:. On January 16, 2025, the Food and Drug Administration approved sotorasib (Lumakras, Amgen Inc.) with panitumumab (Vectibix, Amgen Inc.) for adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as determined by an FDA-approved test, who have received prior ...

Dec 14, 2021 · In colorectal cancer preclinical models, it has been shown that increased EGFR signalling is the primary resistance mechanism, thereby providing a rationale for combining selective KRAS G12C inhibitors with anti-EGFR-therapy. 7 Two combination studies reported encouraging results.

Dec 5, 2023 · Divarasib, a KRAS G12C inhibitor, has shown modest activity as a single agent in KRAS G12C -positive CRC at 400 mg. Epidermal growth factor receptor has been recognized as a major upstream...

Metastatic colorectal cancer patients with mutated KRAS G12C who received the KRAS inhibitor sotorasib in combination with panitumumab, a monoclonal antibody, had a longer progression-free survival compared to their counterparts who underwent standard treatment.